Mirum Pharmaceuticals, Inc. - Common Stock (MIRM)

Historical Holders from Q3 2019 to Q3 2025

Symbol
MIRM on Nasdaq
CUSIP
604749101
Type / Class
Equity / Common Stock
Shares outstanding
51.4M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
57.3M
Holdings value
$4.2B
% of all portfolios
0.007%
Grand Portfolio weight change
+0%
Number of holders
266
Number of buys
160
Number of sells
-91
Average Value change %
0%
Average buys %
+0.001%
Average sells %
-0.002%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Mirum Pharmaceuticals, Inc. - Common Stock (MIRM)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
JANUS HENDERSON GROUP PLC 10.6% +6% $388M $31.9M 5.45M +8.95% JANUS HENDERSON GROUP PLC Nov 28, 2025
Frazier Life Sciences IX, L.P. 7.4% 0% $274M 3.74M 0% James N. Topper Nov 1, 2025
EVENTIDE ASSET MANAGEMENT, LLC 5.43% $108M 2.61M Eventide Asset Management, LLC Dec 31, 2024
BIOTECHNOLOGY VALUE FUND L P 3% $110M 1.5M BVF PARTNERS L P/IL Sep 30, 2025

Institutional Holders of Mirum Pharmaceuticals, Inc. - Common Stock (MIRM)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 57.3M $4.2B +$133M $73.31 266
2025 Q2 55.4M $2.82B +$70.4M $50.89 211
2025 Q1 54.1M $2.44B +$49.1M $45.05 213
2024 Q4 53M $2.19B -$16.4M $41.35 204
2024 Q3 53.1M $2.07B -$12.7M $39.00 178
2024 Q2 53.4M $1.82B +$11.9M $34.19 160
2024 Q1 53.2M $1.34B +$75.9M $25.12 168
2023 Q4 49.7M $1.47B -$8.75M $29.52 185
2023 Q3 48.7M $1.54B +$392M $31.60 157
2023 Q2 36.9M $956M +$63.1M $25.87 144
2023 Q1 34.7M $833M +$34M $24.02 114
2022 Q4 33.3M $650M -$12.4M $19.50 101
2022 Q3 33.7M $709M +$93.2M $21.01 106
2022 Q2 29.3M $568M +$47.5M $19.46 103
2022 Q1 26.8M $590M -$6.24M $22.02 98
2021 Q4 22.9M $365M +$18.8M $15.95 80
2021 Q3 21.4M $427M +$2.08M $19.92 69
2021 Q2 21.5M $371M +$643K $17.29 66
2021 Q1 21.5M $425M -$8.43M $19.82 60
2020 Q4 22M $384M +$52.3M $17.46 71
2020 Q3 18.7M $361M -$1.29M $19.27 50
2020 Q2 18.8M $366M +$8.94M $19.46 57
2020 Q1 18.6M $260M +$32.1M $14.00 43
2019 Q4 16.2M $398M +$12.8M $24.52 39
2019 Q3 16.5M $166M +$166M $10.06 38